Astria Therapeutics, Inc. (NASDAQ:ATXS) Short Interest Down 18.1% in November

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a significant drop in short interest in November. As of November 15th, there was short interest totalling 2,900,000 shares, a drop of 18.1% from the October 31st total of 3,540,000 shares. Based on an average trading volume of 321,000 shares, the days-to-cover ratio is currently 9.0 days. Currently, 6.0% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several analysts have issued reports on ATXS shares. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Thursday, November 14th. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Oppenheimer raised their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Finally, Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $25.60.

Institutional Trading of Astria Therapeutics

Several large investors have recently added to or reduced their stakes in ATXS. Vanguard Group Inc. grew its holdings in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after buying an additional 480,184 shares in the last quarter. Tidal Investments LLC acquired a new position in Astria Therapeutics in the 1st quarter worth about $1,664,000. Vestal Point Capital LP raised its stake in shares of Astria Therapeutics by 23.1% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after purchasing an additional 750,000 shares in the last quarter. Sofinnova Investments Inc. acquired a new stake in shares of Astria Therapeutics during the 2nd quarter valued at about $552,000. Finally, ClariVest Asset Management LLC bought a new stake in shares of Astria Therapeutics in the 2nd quarter valued at approximately $731,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS traded up $0.11 on Monday, reaching $10.50. 86,539 shares of the company traded hands, compared to its average volume of 599,522. The stock has a market capitalization of $592.52 million, a PE ratio of -4.97 and a beta of 0.71. The company’s 50 day moving average is $11.10 and its 200-day moving average is $10.64. Astria Therapeutics has a fifty-two week low of $4.67 and a fifty-two week high of $16.90.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.